What is montair
Montair is a widely prescribed oral medication containing Montelukast sodium as its active pharmaceutical ingredient. Montelukast belongs to a class of drugs known as leukotriene receptor antagonists, which are among the most important medications available for the long-term management of asthma and allergic rhinitis. Leukotrienes are potent inflammatory mediators produced by various cells of the immune system, including mast cells, eosinophils, and basophils, and they play a central role in the pathophysiology of asthma and allergic conditions. These cysteinyl leukotrienes, primarily LTC4, LTD4, and LTE4, are released during allergic reactions and trigger bronchoconstriction, mucus secretion, airway edema, and the recruitment of inflammatory cells into the airways. Montelukast works by selectively and potently blocking the cysteinyl leukotriene type 1 receptor on airway smooth muscle cells, vascular endothelial cells, and inflammatory cells, thereby preventing the cascade of events that lead to airway narrowing, inflammation, and the symptoms of asthma and allergic rhinitis. Unlike inhaled bronchodilators that provide rapid relief of acute symptoms, Montair is a controller medication that is taken regularly to maintain long-term control of chronic respiratory conditions. The medication was developed by Merck and has been available as a prescription and over-the-counter medication in many countries for more than two decades. Montair is available in several oral formulations, including conventional tablets, chewable tablets for pediatric use, and oral granules for young children who cannot swallow tablets. The medication has an established track record of safety and efficacy and is included in national and international guidelines for the management of asthma and allergic rhinitis. Montair changed the management of mild persistent asthma and exercise-induced bronchoconstriction, providing an oral alternative to inhaled corticosteroids for patients who prefer or require tablet-based therapy.
How does montair work
The therapeutic mechanism of Montair centers on its ability to potently and selectively antagonize the cysteinyl leukotriene type 1 receptor, which is the primary receptor through which leukotrienes mediate their pathological effects in the airways. Cysteinyl leukotrienes, including leukotriene C4, leukotriene D4, and leukotriene E4, are synthesized from arachidonic acid through the 5-lipoxygenase pathway in activated mast cells, eosinophils, basophils, and other inflammatory cells. These lipid mediators are among the most potent bronchoconstrictor substances known, being approximately one thousand times more potent than histamine at causing contraction of airway smooth muscle. They also increase vascular permeability, leading to airway edema, stimulate mucus secretion that can plug the airways, and recruit additional inflammatory cells including eosinophils and neutrophils to the airways, amplifying the inflammatory response. Under normal conditions, the production of leukotrienes is tightly regulated, but in asthma and allergic conditions, excessive leukotriene synthesis occurs, driving the pathological processes that underlie these diseases. Montelukast binds with high affinity to the cysteinyl leukotriene type 1 receptor, a G protein-coupled receptor expressed on airway smooth muscle cells, vascular endothelial cells, and various inflammatory cells. By occupying this receptor, Montelukast prevents leukotrienes from binding and activating their downstream signaling pathways, thereby inhibiting bronchoconstriction, reducing vascular permeability, and attenuating the inflammatory response. Unlike inhaled corticosteroids, which broadly suppress multiple inflammatory pathways by modulating gene transcription, Montelukast provides targeted inhibition of a specific inflammatory pathway. This more selective mechanism of action contributes to the favorable safety profile of the medication and means that it is generally less effective than inhaled corticosteroids as monotherapy for persistent asthma. Montelukast also has effects on airway remodeling, the structural changes that occur in the airways of patients with chronic asthma, including subepithelial fibrosis, smooth muscle hypertrophy, and mucus gland hyperplasia. By reducing chronic inflammation and the downstream effects of leukotrienes on airway structural cells, Montelukast may attenuate the progression of airway remodeling over time. The medication has a rapid onset of action relative to other controller therapies, with protection against bronchoconstriction evident within hours of the first dose. This rapid onset is particularly useful for the prevention of exercise-induced bronchoconstriction, where the medication can be taken shortly before exercise to prevent airway narrowing. Montelukast also has clinically meaningful effects on nasal symptoms, as leukotrienes are involved in the pathogenesis of allergic rhinitis, contributing to nasal congestion, rhinorrhea, and nasal inflammation. The medication’s ability to address both upper and lower airway symptoms makes it a particularly attractive option for patients who have both asthma and allergic rhinitis.
Indications and clinical uses
Montair is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients from six months of age and older. The medication is used for the long-term control of persistent asthma, including the prevention of both daytime and nighttime asthma symptoms. For patients with mild persistent asthma who require controller therapy, Montair provides an oral alternative to low-dose inhaled corticosteroids. While inhaled corticosteroids remain the preferred first-line controller therapy for persistent asthma in most clinical practice guidelines, Montair is an appropriate option for patients who cannot or will not use inhaled medications, who experience significant side effects from inhaled corticosteroids, or who have concurrent allergic rhinitis. The medication is particularly useful for the management of exercise-induced bronchoconstriction, a condition in which physical exertion triggers airway narrowing, resulting in coughing, wheezing, and shortness of breath. Montair, when taken two hours before exercise, provides significant protection against exercise-induced bronchoconstriction for up to twenty-four hours, allowing for greater flexibility in physical activity compared to short-acting bronchodilators, which must be administered immediately before exercise. The medication is also indicated for the relief of symptoms of seasonal allergic rhinitis, commonly known as hay fever, which affects millions of individuals worldwide. For patients whose nasal symptoms are inadequately controlled with antihistamines or who prefer a single medication for both their asthma and allergic rhinitis, Montair offers a convenient once-daily treatment option. Perennial allergic rhinitis, which causes year-round nasal symptoms due to allergens such as dust mites, animal dander, and mold, is also an approved indication for Montair. The medication has been shown to improve daytime and nighttime nasal symptoms, including congestion, rhinorrhea, itching, and sneezing, and quality of life measures in patients with allergic rhinitis. In addition to these primary indications, Montair has been studied for several off-label uses where leukotrienes are believed to contribute to disease pathogenesis. Chronic urticaria, or hives, which can be difficult to manage with antihistamines alone, has shown responsiveness to Montelukast in some patients, particularly those whose urticaria is exacerbated by aspirin or nonsteroidal anti-inflammatory drugs. Aspirin-exacerbated respiratory disease, characterized by asthma, nasal polyposis, and sensitivity to aspirin and other cyclooxygenase-1 inhibitors, has been treated with Montelukast, which can improve asthma control and nasal symptoms in these patients. Atopic dermatitis, or eczema, has been studied as a potential indication for Montelukast, with some studies showing modest benefits. The medication has also been evaluated for the prevention of bronchiolitis in infants, the treatment of chronic obstructive pulmonary disease, and the management of eosinophilic esophagitis, although the evidence for these off-label uses is variable and Montelukast is not approved for these indications.
Dosage and administration guidelines
The dosing of Montair varies according to the age of the patient and the specific condition being treated. For adults and adolescents fifteen years of age and older, the recommended dose is one 10 mg tablet taken once daily in the evening. The timing of administration in the evening is based on the circadian variation in airway inflammation, which tends to be greatest during the early morning hours, and on clinical trials that demonstrated superior outcomes with evening dosing compared to morning dosing. For pediatric patients aged six to fourteen years, the recommended dose is one 5 mg chewable tablet taken once daily in the evening. The chewable tablet formulation is flavored to improve palatability and should be chewed thoroughly before swallowing. For children aged two to five years, the recommended dose is one 4 mg chewable tablet or one packet of 4 mg oral granules taken once daily in the evening. For infants aged six months to twenty-three months, the recommended dose is one packet of 4 mg oral granules taken once daily in the evening. The oral granules can be administered directly into the mouth or mixed with a spoonful of soft food, such as applesauce or mashed carrots, that is at room temperature. The granules should not be mixed with liquid, as the medication is not stable in liquid vehicles. The mixture of granules and food should be consumed immediately and should not be stored for later use. Montair should be taken regularly every day, even when the patient is asymptomatic, as the medication is intended for the long-term control of chronic conditions and does not provide immediate relief of acute symptoms. Patients who experience an acute asthma exacerbation should use their short-acting bronchodilator as prescribed and should not rely on Montair for rescue therapy. If a dose of Montair is missed, the patient should take the missed dose as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Patients should not take a double dose to make up for a missed dose, as this could increase the risk of adverse effects. The medication can be taken with or without food, as food does not affect the bioavailability of Montelukast. However, the oral granules should be mixed with food as described above. No dosage adjustment is required for elderly patients, patients with renal impairment, or patients with mild to moderate hepatic impairment. The safety and efficacy of Montelukast in patients with severe hepatic impairment have not been established, and caution is recommended in this population. The duration of therapy with Montair is indefinite for chronic conditions such as persistent asthma and perennial allergic rhinitis, and treatment should be continued as long as the patient derives clinical benefit. For seasonal allergic rhinitis, Montair can be taken during the allergy season and discontinued when the season ends, although pre-seasonal initiation of therapy may provide more effective symptom control.
Administration Guidelines by Formulation:
- Conventional 10 mg tablets should be swallowed whole with a glass of water
- Chewable 5 mg and 4 mg tablets should be chewed thoroughly before swallowing
- Oral granules should be emptied onto a spoonful of room-temperature soft food and consumed immediately
- Oral granules must not be mixed with any liquid, as the drug is not stable in solution
- Take Montair once daily in the evening for asthma and allergic rhinitis
- For exercise-induced bronchoconstriction, take at least two hours before exercise
- Do not take an additional dose within 24 hours for exercise-induced bronchoconstriction
- Montair is not for acute asthma attacks; use a short-acting bronchodilator for rescue
- Store at room temperature, protected from light and moisture
- Keep all formulations out of reach of children
Clinical efficacy and research evidence
The efficacy of Montelukast in the long-term management of asthma and allergic rhinitis has been shown through a comprehensive program of randomized controlled clinical trials involving thousands of patients across multiple age groups and disease severities. In adults and adolescents with persistent asthma, Montelukast 10 mg once daily has consistently shown significant improvements in multiple measures of asthma control compared to placebo, including forced expiratory volume in one second, morning and evening peak expiratory flow rate, daytime and nighttime asthma symptoms, use of rescue bronchodilator medication, and asthma exacerbation rates. A landmark clinical trial involving over 1,500 patients demonstrated that Montelukast reduced asthma exacerbation days by approximately 30 percent compared to placebo and improved quality of life scores as measured by validated asthma-specific instruments. Head-to-head comparative trials have shown that while inhaled corticosteroids such as beclomethasone and fluticasone are more effective than Montelukast as monotherapy for persistent asthma, Montelukast offers comparable efficacy in some patient subgroups and is associated with a lower incidence of local side effects such as oral thrush and dysphonia. In pediatric populations, Montelukast has demonstrated significant efficacy in reducing asthma exacerbations and improving lung function. A large trial in children aged two to five years with intermittent asthma showed that Montelukast reduced the rate of asthma exacerbations by approximately 30 percent compared to placebo. In children aged six to fourteen years, Montelukast 5 mg chewable tablet taken once daily improved lung function, reduced rescue medication use, and improved quality of life scores. For exercise-induced bronchoconstriction, Montelukast has been shown to provide significant protection against the fall in forced expiratory volume in one second that occurs following exercise challenge. The protective effect is evident within two hours of dosing and lasts for up to twenty-four hours, providing all-day coverage for exercise-induced symptoms. This is a significant advantage over short-acting beta agonists, which provide protection for only two to four hours. In allergic rhinitis, clinical trials have demonstrated that Montelukast 10 mg once daily improves daytime and nighttime nasal symptoms, eye symptoms, and quality of life compared to placebo. The magnitude of improvement is comparable to that achieved with loratadine, a commonly used second-generation antihistamine. The combination of Montelukast with an antihistamine has been shown in multiple studies to provide superior symptom control compared to either agent alone, suggesting complementary mechanisms of action. For patients with both asthma and allergic rhinitis, Montelukast provides the advantage of treating both conditions with a single medication, which can simplify the medication regimen, improve adherence, and reduce the total burden of pharmacotherapy. Real-world effectiveness studies, including large observational cohorts and database analyses, have confirmed the clinical trial findings and demonstrated that Montelukast is effective in routine clinical practice, where adherence may be less than optimal and where patients often have comorbid conditions that were excluded from clinical trials. Economic analyses have suggested that Montelukast is cost-effective for the management of asthma, particularly in patients who also have allergic rhinitis, due to the reduction in healthcare resource utilization associated with improved disease control.
Buy Montair(Montelukast) Over The Counter at Happy Family Pharmacy
Side effects and adverse reactions
Montair is generally well-tolerated, and clinical trials have demonstrated that the overall incidence of adverse events with Montelukast is comparable to that observed with placebo. The most commonly reported adverse events include headache, which occurs in a small percentage of patients and is generally mild and self-limited. Gastrointestinal disturbances, including abdominal pain, nausea, diarrhea, and dyspepsia, have been reported and may be more common in children than in adults. These effects are typically transient and do not require discontinuation of therapy in the majority of cases. Upper respiratory tract infections and pharyngitis have been reported in clinical trials, although these may represent intercurrent illnesses rather than true drug-related adverse effects. Fever has been noted in pediatric patients receiving Montelukast, particularly in the youngest age groups, but a causal relationship has not been definitively established. Otitis media has been reported more frequently in Montelukast-treated children compared to placebo in some studies, although this finding has not been consistently replicated. Hypersensitivity reactions, including urticaria, angioedema, and pruritus, have been reported in post-marketing surveillance and may occur within hours to days of initiating therapy. Patients who develop signs of an allergic reaction, including rash, swelling of the face or lips, or difficulty breathing, should discontinue the medication and seek medical attention. Neuropsychiatric adverse events have emerged as a significant safety concern with Montelukast based on post-marketing surveillance data. The range of reported neuropsychiatric effects is broad and includes agitation, aggressive behavior, hostility, anxiety, depression, disorientation, disturbance in attention, dream abnormalities, hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thinking and behavior, and tremor. The exact incidence of these events is difficult to determine, but they are considered uncommon. The neuropsychiatric effects of Montelukast have been reported in both adults and children, although some reports suggest that children may be more susceptible to certain effects, including sleep disturbances and behavioral changes. The mechanism underlying these neuropsychiatric effects is not fully understood but may involve the penetration of Montelukast into the central nervous system and its interaction with leukotriene receptors in the brain. In 2020, the United States Food and Drug Administration issued a boxed warning regarding serious neuropsychiatric events associated with Montelukast, recommending that the medication be reserved for patients who do not respond adequately to or cannot tolerate other asthma or allergy medications. Eosinophilic conditions, including eosinophilic vasculitis presenting as Churg-Strauss syndrome, have been reported in patients receiving Montelukast for the treatment of asthma. In most cases, the development of Churg-Strauss syndrome during Montelukast therapy has been associated with the reduction or withdrawal of oral corticosteroid therapy, suggesting that the syndrome is the unmasking of a pre-existing condition rather than a direct effect of Montelukast. Nevertheless, patients who develop eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, or neuropathy should be evaluated for the possibility of Churg-Strauss syndrome. Hepatic adverse effects, including elevated liver enzymes and rare cases of hepatitis, have been reported. Musculoskeletal effects, including arthralgia and myalgia, have been documented in post-marketing reports. Bleeding events, including epistaxis and bruising, have been observed, although a direct causal relationship has not been firmly established. The medication does not appear to cause clinically significant cardiovascular, renal, or endocrine toxicity, and routine laboratory monitoring is not required during therapy.
Drug interactions
The potential for clinically significant drug interactions with Montair is relatively low compared to many other medications used for asthma and allergic conditions, which is one of the advantages of this selective leukotriene receptor antagonist. Montelukast is metabolized primarily by cytochrome P450 3A4 and 2C9 isoenzymes in the liver, but it is a weak substrate for these enzymes, and drugs that inhibit or induce these pathways do not have clinically significant effects on Montelukast pharmacokinetics. Phenobarbital, a potent inducer of multiple cytochrome P450 enzymes, has been shown to reduce the area under the plasma concentration-time curve of Montelukast by approximately 40 percent when the two drugs are co-administered. However, this interaction is not generally considered to be clinically significant, and no dosage adjustment for Montelukast is recommended for patients taking phenobarbital. Rifampicin, another potent enzyme inducer used in the treatment of tuberculosis, may similarly reduce Montelukast levels, but specific interaction studies have not been conducted, and no dosage adjustment is recommended. Montelukast does not inhibit or induce cytochrome P450 enzymes at clinically relevant concentrations, and it is not expected to alter the metabolism of other drugs. This is an important consideration in elderly patients and in patients with multiple comorbidities who may be taking numerous medications, as it reduces the complexity of managing potential drug interactions. Montelukast has been co-administered with a wide variety of medications commonly used in patients with asthma and allergic rhinitis without evidence of significant interactions. Inhaled corticosteroids, including beclomethasone, budesonide, fluticasone, and mometasone, have been used in combination with Montelukast without interaction, and the combination is frequently employed in clinical practice for the management of moderate persistent asthma. Oral corticosteroids, including prednisone and methylprednisolone, have been used with Montelukast, and no interaction has been identified. Short-acting and long-acting beta agonists, including albuterol, formoterol, and salmeterol, are frequently co-prescribed with Montelukast, and no pharmacokinetic or pharmacodynamic interactions have been observed. Theophylline, a bronchodilator with a narrow therapeutic index, has been shown not to interact with Montelukast in specific drug interaction studies, allowing for the safe co-administration of these agents. Antihistamines, including loratadine, cetirizine, and fexofenadine, are commonly used with Montelukast for the management of allergic rhinitis, and the combination has been shown to be safe and to provide additive clinical benefits. Oral contraceptives, including ethinyl estradiol and norethindrone, do not interact with Montelukast, and no adjustment of contraceptive therapy is required. Warfarin, an anticoagulant with numerous drug interactions, has been studied with Montelukast, and no effect on the international normalized ratio was observed. However, as with any new medication in a patient receiving warfarin, monitoring of the INR is recommended. Nonsteroidal anti-inflammatory drugs, which can trigger bronchoconstriction in some patients with asthma, do not interact with Montelukast at the pharmacokinetic level, although the clinical interaction between asthma and nonsteroidal anti-inflammatory drugs remains an important consideration. Antacids and histamine-2 receptor antagonists used for gastroesophageal reflux disease, which is common in patients with asthma, do not affect the absorption or metabolism of Montelukast. Grapefruit juice, which inhibits intestinal CYP3A4, does not affect Montelukast pharmacokinetics, and patients do not need to avoid grapefruit products while taking the medication. Despite the low potential for drug interactions, patients should maintain a current list of all medications, including over-the-counter products and herbal supplements, and share this list with their healthcare provider to allow for a comprehensive assessment of potential interactions.
Contraindications and precautions
Montair is contraindicated in patients with known hypersensitivity to Montelukast or any of the excipients in the formulation, including mannitol, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and the film-coating materials. Patients who have experienced allergic reactions, including urticaria, angioedema, or anaphylaxis, following a previous dose of Montelukast should not receive the medication. The medication is not indicated for the immediate relief of acute asthma exacerbations, and patients should have a short-acting bronchodilator available for rescue therapy. Patients who experience an acute asthma attack while on Montair should not increase their dose of Montelukast to manage the exacerbation but should instead use their prescribed rescue medication and seek medical attention if symptoms persist or worsen. The neuropsychiatric adverse effects of Montelukast are a significant concern, and patients and caregivers should be counseled about these risks before initiating therapy. Patients should be instructed to be alert for changes in mood, behavior, or cognitive function and to report these changes promptly to their healthcare provider. The medication should be discontinued if significant neuropsychiatric symptoms develop, and alternative therapies for asthma and allergic rhinitis should be considered. Given the neuropsychiatric safety concerns, Montelukast should generally be reserved for patients who have not responded adequately to or who cannot tolerate alternative therapies, including inhaled corticosteroids for asthma and intranasal corticosteroids or antihistamines for allergic rhinitis. The potential for eosinophilic conditions, including Churg-Strauss syndrome, should be considered in patients who develop systemic symptoms such as worsening pulmonary function, cardiac complications, or peripheral neuropathy, particularly in corticosteroid tapering. Patients who develop these symptoms should be evaluated urgently, and Montelukast should be discontinued if an eosinophilic condition is suspected. The safety of Montelukast during pregnancy has not been established with certainty, and the medication is classified as pregnancy category B by the United States Food and Drug Administration. Animal reproduction studies have not demonstrated fetal harm, but there are no well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if the potential benefits outweigh the potential risks. Pregnant patients with asthma should be counseled that uncontrolled asthma poses significant risks to both the mother and the fetus, including preeclampsia, preterm birth, low birth weight, and maternal mortality, and that appropriate pharmacological management of asthma during pregnancy is recommended. Montelukast is excreted in the breast milk of lactating animals, but it is not known whether the drug is excreted in human breast milk. Caution should be exercised when administering Montelukast to a nursing mother, and the decision to continue breastfeeding should consider the importance of the medication to the mother’s health. The safety and efficacy of Montelukast in infants less than six months of age have not been established, and the medication should not be used in this population. Geriatric patients, defined as those aged sixty-five years and older, may be at increased risk of neuropsychiatric adverse effects from Montelukast, and the decision to use the medication in this population should incorporate an individualized assessment of risks and benefits. Patients with phenylketonuria should be aware that the 4 mg and 5 mg chewable tablets contain aspartame, a source of phenylalanine, and should take this into account in their dietary management. Patients with severe hepatic impairment should be monitored closely, as the safety of Montelukast in this population has not been specifically studied. The medication should not be abruptly substituted for other controller therapies, particularly oral or inhaled corticosteroids. When transitioning from corticosteroid therapy to Montelukast, a gradual tapering schedule should be followed, and patients should be monitored for signs of adrenal insufficiency and worsening of airway inflammation.